Working… Menu
Trial record 1 of 1 for:    NCT03762850
Previous Study | Return to List | Next Study

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03762850
Recruitment Status : Active, not recruiting
First Posted : December 4, 2018
Last Update Posted : June 23, 2021
Information provided by (Responsible Party):
Travere Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : April 2023